A

Amgen

Makes biotech medicines for serious illnesses

Regulatory Affairs Manager

Full-TimeUpdated on 10/24/2026
No salary listed
Mid
Bachelor's, Master's, PhD
Seoul, South Korea
In Person
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • Knowledge of regulatory principles, policies, procedures, and standard operating procedures.
  • Comprehensive understanding of regulatory activities and their impact on other projects and processes.
  • General knowledge of national legislation and regulations relating to medicinal products.
  • General awareness of the country's registration procedures and challenges for clinical trial applications, marketing authorizations, and lifecycle management activities.
  • Knowledge and experience in the country's regulatory environment relevant to the product area and development stage.
  • Understanding of drug development.
  • Ability to communicate scientific and clinical information.
  • Ability to resolve conflicts and develop a course of action leading to a beneficial outcome.
  • Doctorate or master's degree in a scientific area and 3 years of directly related experience, or a bachelor's degree in a scientific area and 5 years of directly related experience.
Responsibilities
  • Provide country regulatory expertise and execution for the development, registration, and lifecycle management of assigned products.
  • Assist in aligning local regulatory requirements with corporate standards.
  • Provide national or regional input to regulatory strategies and execute them.
  • Plan and manage local regulatory submissions in compliance with corporate standards and local requirements.
  • Ensure local labels are developed and maintained in line with local legislation and company standards and procedures.
  • Act as the point of contact with regulatory agencies and participate in local agency interactions and their preparation.
  • Develop, communicate, and coordinate regulatory strategy for the pipeline.
  • Plan and manage clinical trial applications through contract research organizations and coordinate responses to queries between the contract research organization and the company.
  • Manage contract research organization invoices and participate in the global network.
  • Serve as the primary point of contact and oversight between the in-country functional service provider and the company, ensuring delivery according to contract, timelines, and quality requirements for regulatory and safety filings.
  • Contribute to filing plans for marketing authorization and lifecycle maintenance in discussion with the local cross-functional team.
  • Execute country filing plans for marketing authorization and lifecycle maintenance under general supervision.
  • Ensure regulatory submissions are timely and meet corporate and local regulatory requirements.
  • Create, review, and approve source text for country labeling, and own country artwork based on the source text.
  • Collaborate with Regional and Global Study Operations teams to support local planning and execution of clinical studies in accordance with national legal and regulatory requirements where appropriate.
  • Review and approve promotional and non-promotional materials.
  • Monitor changes in local trade associations and national legislation, and communicate their impact to local and regional groups.
  • Monitor the external regulatory environment to inform and advise regulatory decision-making.
  • Ensure or support regulatory product compliance, including regulatory information management, post-marketing commitments, pediatric and other agency commitments, and renewals.
  • Exchange regulatory information and intelligence with regulatory colleagues and cross-functional teams, and provide timely advice on local regulatory considerations and regulations.
  • Partner with International Regulatory Leads to support regulatory development, registration, and lifecycle management.
  • Partner with peers to ensure procedural consistency.
  • Establish relationships with agency staff for assigned products where applicable.
  • Establish regular contacts and interactions with distributors where applicable.
  • Assist with local healthcare compliance activities where applicable.
  • Participate in local regulatory process improvements, initiatives, and training.
  • Oversee external vendor and contractor relationships where applicable.
Desired Qualifications
  • A degree and in-depth regulatory experience and/or experience related to the country.
  • In-depth knowledge of country legislation and regulations relating to medicinal products.
  • Experience planning, submitting, and obtaining approval for a new drug application.
  • Experience with clinical trial applications and negotiation with the Ministry of Food and Drug Safety.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 24th, 2026
Amgen vs Johnson & Johnson: cheaper Amgen edges J&J's $94.2B revenue giant on valuation

A Motley Fool comparison of Amgen and Johnson & Johnson (J&J) favours Amgen, mainly on price. Amgen's forward price-to-earnings ratio is 19.4x, against 24.1x for J&J. In 2025, Amgen's revenue rose about 10% to $36.7 billion, with net income of $7.7 billion. J&J's revenue grew 6% to $94.2 billion, with net income of $26.8 billion and free cash flow of $19.7 billion. Amgen carries far more debt: its debt-to-equity ratio is nearly 6.3x, against about 0.6x for J&J. Three wholesalers account for 77% of its gross revenues. Amgen also struck a deal with the US government that exempts it from pharmaceutical tariffs for three years in return for price cuts on two drugs. J&J expects revenue of $101 billion this fiscal year, and Amgen expects about $37.8 billion.

Yahoo Finance
Oct 22nd, 2026
Eli Lilly vs Amgen: $65.2B revenue and 45% growth against a cheaper stock for 2026

Eli Lilly is growing far faster than Amgen, but investors pay a steep premium for it. The article's author favours Lilly for long-term investors in 2026. Lilly's FY 2025 revenue rose 45% to about $65.2 billion, with net income of $20.6 billion and a 32% net margin. Amgen's revenue grew about 10% to $36.7 billion, with net income of $7.7 billion and a 21% margin. Lilly trades at a forward P/E of 38.3x against Amgen's 19.4x. Its debt-to-equity ratio is about 1.6x, compared with nearly 6.3x for Amgen. Lilly's growth rests on its GLP-1 drugs Zepbound and Mounjaro. The article projects 2026 revenue of $88.7 billion, against about $37.8 billion for Amgen.

Yahoo Finance
Oct 21st, 2026
Amgen's focus shifts to six growth drivers and MariTide as rare disease sales hit $1.6B

Amgen now frames its story around six key growth drivers, which grew 26% from a year earlier in fiscal Q2 2026 and made up nearly 70% of product sales. Rare disease, once reported on its own, is one of the six. The rare disease portfolio grew 21% to $1.6 billion, about 16% of quarterly revenue. Total revenue rose 9.5%, and management raised its 2026 revenue guidance to between $38.2 billion and $39.4 billion. Management also highlighted MariTide, an obesity drug in Phase III trials. Amgen wants it to be the first monthly or less frequent obesity therapy and is already scaling up manufacturing. One risk sits in rare disease. On September 1, 2026, Britain's medicines regulator suspended Tavneos for new patients, citing an unreliable main study. The drug made $119 million in fiscal Q1 2026. Amgen's next report is expected around November 3, 2026.

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.